Faculty Information - Hiroki Ishihara

（Last updated : 2024-03-22 15:59:44）

Hiroki Ishihara
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Department of Urology

Position Assistant Professor

■ Published papers

1.	Original article	Renal cell carcinoma outcomes in end-stage renal disease: A 40-year study from two Japanese institutions. 2024/01
2.	Original article	A single-center retrospective comparative analysis of urinary continence in robotic prostatectomy with a combination of umbilical ligament preservation and Hood technique. 2023/10
3.	Original article	Predictive factors and oncological outcomes of pathological T3a upstaging in patients with clinical T1 renal cell carcinoma undergoing partial nephrectomy. 2023/10
4.	Original article	Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma. 2023/10
5.	Original article	Editorial Comment to Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study. 2023/09
6.	Original article	Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. 2023/07
7.	Review article	Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. 2023/07
8.	Original article	Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of patients with advanced renal cell carcinoma outside of clinical trials: A real-world retrospective multi-institutional study. 2023/03
9.	Original article	Editorial Comment on Disease-free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results-Medicare data. 2023/03
10.	Original article	Continuation of immune checkpoint inhibitors for newly developed brain metastasis during immune checkpoint inhibitor treatment for oligoprogressive metastatic renal cell carcinoma. 2023/02
11.	Original article	Impact of body mass index on outcomes in an asian population of advanced renal cell carcinoma and urothelial carcinoma treated with immune checkpoint inhibitors. 2023/02
12.	Original article	Comparison of the impact of immune-related adverse events due to immune checkpoint inhibitor dual combination therapy and immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy in patients with advanced renal cell carcinoma. 2023/01
13.	Original article	Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up. 2022/07/08
14.	Original article	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy of Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria 2022/07/05
15.	Original article	Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. 2022/02
16.	Original article	Association Between Anesthetic Technique and Survival After Radical Nephroureterectomy: A Propensity Score-matching Study. 2022/01
17.	Original article	Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. 2022/01
18.	Original article	Assessment of Feasibility of Robot-assistted Radical Cystectomy in Patients With Advanced Bladder Cancer Treated With Maintenance Hemodialysis Therapy 2022
19.	Original article	Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma 2021/12
20.	Original article	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. 2021/12
21.	Original article	Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy. 2021/12
22.	Original article	Association between ureteral clamping time and acute kidney injury during robot-assisted radical cystectomy. 2021/11
23.	Original article	Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease: a multi-institutional central pathology study. 2021/10
24.	Original article	Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. 2021/10
25.	Original article	Tumor response in primary kidney lesions and metastatic lesions in nivolumab plus ipilimumab therapy for advanced renal cell carcinoma without prior nephrectomy: Preliminary results of a multi-institutional study. 2021/10
26.	Original article	Albumin-to-alkaline phosphatase ratio as a novel prognostic marker of nivolumab monotherapy for previously treated metastatic renal cell carcinoma. 2021/09
27.	Original article	Prognostic impact of trial-eligibility criteria in patients with metastatic renal cell carcinoma 2021/08
28.	Original article	Prognostic impact of early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events as first-line therapy for metastatic renal cell carcinoma: A multi-institution retrospective study. 2021/07
29.	Original article	Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma. 2021/06
30.	Original article	Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data. 2021/05
31.	Original article	Effect of improved systemic therapy on patient survival in metastatic non-clear-cell renal cell carcinoma. 2021/05
32.	Original article	Impact of sarcopenia on post-operative outcomes following nephrectomy and tumor thrombectomy for renal cell carcinoma with inferior vena cava thrombus. 2021/04
33.	Original article	Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. 2021/04
34.	Original article	Predictive impact of prognostic nutritional index on pembrolizumab for metastatic urothelial carcinoma resistant to platinum-based chemotherapy. 2021/03
35.	Original article	Predictive role of γ‑glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma. 2021/03
36.	Original article	The controlling nutritional status CONUT score in patients with advanced bladder cancer after radical cystectomy. 2021/03
37.	Original article	Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy. 2021/02
38.	Original article	Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions. 2021/01
39.	Original article	Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. 2021/01
40.	Original article	Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end‐stage renal disease. 2020/11
41.	Original article	Nivolumab treatment beyond progression for metastatic renal cell carcinoma: New role of metastasectomy in the immune checkpoint inhibitor era? 2020/08
42.	Original article	Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer. 2020/08
43.	Original article	The de ritis (aspartate transaminase/alanine transaminase) ratio as a prognosticator in patients with end-stage renal disease-associated renal cell carcinoma. 2020/06
44.	Original article	Efficacy of axitinib after nivolumab failure in metastatic renal cell carcinoma. 2020/05
45.	Original article	Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era. 2020/05
46.	Original article	Predictive factors for recurrence after partial nephrectomy for clinical T1 renal cell carcinoma: a retrospective study of 1227 cases from a single institution. 2020/05
47.	Original article	Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. 2020/05
48.	Original article	Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. 2020/04
49.	Review article	Unique behavior of brain metastases during the treatment of nivolumab for metastatic renal cell carcinoma. 2019/12
50.	Original article	Efficacy and safety of axitinib for metastatic renal cell carcinoma in patients on hemodialysis for end-stage renal disease: Case series of eight patients. 2019/11
51.	Original article	Negative effect of immediate sunitinib interruption on survival in patients with metastatic renal cell carcinoma. 2019/11
52.	Original article	Negative Effect of Immediate Sunitinib Interruption on Survival in Patients With Metastatic Renal Cell Carcinoma. 2019/11
53.	Original article	Newly developing brain metastases during nivolumab therapy for metastatic renal cell carcinoma: A case series in two Japanese institutions. 2019/08
54.	Original article	Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. 2019/08
55.	Original article	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers. 2019/08
56.	Original article	Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. 2019/06
57.	Original article	Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy. 2019/06
58.	Original article	Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. 2019/04
59.	Original article	Prognostic markers for refined stratification of IMDC intermediate-risk metastatic clear cell renal cell carcinoma treated with first-line tyrosine kinase inhibitor therapy. 2019/04
60.	Original article	Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. 2019/03
61.	Original article	Effect of changes in skeletal muscle mass on oncological outcomes during first-line sunitinib therapy for metastatic renal cell carcinoma. 2018/12
62.	Original article	Pancreatic cancer cell fraction estimation in a DNA sample. 2018/12
63.	Original article	DNA methylation marker to estimate the breast cancer cell fraction in DNA samples. 2018/11
64.	Original article	Acquired cystic disease-associated renal cell carcinoma is the most common subtype in long-term dialyzed patients: Central pathology results according to the 2016 WHO classification in a multi-institutional study. 2018/10
65.	Original article	Immediate progressive disease in patients with metastatic renal cell carcinoma treated with nivolumab: a multi-institution retrospective study. 2018/10
66.	Original article	Impact of the Mayo Adhesive Probability Score on the Complexity of Robot-Assisted Partial Nephrectomy. 2018/10
67.	Original article	Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma. 2018/09
68.	Original article	Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma. 2018/07
69.	Original article	Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy. 2018/06
70.	Original article	Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma. 2018/06
71.	Original article	Prognostic impact of the components of progressive disease on survival after first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. 2018/06
72.	Original article	Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. 2017/12
73.	Original article	Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study. 2017/10
74.	Case report	Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Kidney Transplantation: A Multi-Institution Study in Japan Over 30 years. 2017/10
75.	Original article	Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. 2017/09
76.	Original article	Preoperative controlling nutritional status (CONUT) score as a novel predictive biomarker of survival in patients with localized urothelial carcinoma of the upper urinary tract treated with radical nephroureterectomy. 2017/09
77.	Original article	Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy. 2017/09
78.	Original article	Effect of Systemic Inflammation on Survival in Patients With Metastatic Renal Cell Carcinoma Receiving Second-line Molecular-targeted Therapy. 2017/08
79.	Case report	Evaluation of first-line sorafenib treatment for metastatic renal cell carcinoma in kidney transplant patients: A single-center experience with four cases. 2017/08
80.	Original article	Evaluation of microvascular inflammation in ABO-incompatible kidney transplantation. 2017/06
81.	Original article	Evaluation of tumor burden after sequential molecular-targeted therapy in patients with metastatic renal cell carcinoma. 2017/03
82.	Original article	Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy. 2017/02
83.	Original article	Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study. 2017/02
84.	Original article	Sarcopenia and the modified glasgow prognostic score are significant predictors of survival among patients with metastatic renal cell carcinoma who are receiving first-line sunitinib treatment. 2016/10
85.	Original article	Late recurrence of a malignant hypoglycemia-inducing pelvic solitary fibrous tumor secreting high-molecular-weight insulin-like growth factor-II: A case report with protein analysis. 2016/07
86.	Original article	The magnitude of best tumor shrinkage during second-line targeted therapy affects progressionfree survival but not overall survival in patients with metastatic renal cell carcinoma. 2016/06
87.	Original article	Post-transplant lymphoproliferative disorder in kidney transplant recipients: A single-center experience in Japan. 2016/04
88.	Original article	The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma. 2016/03
89.	Original article	Effects of low-dose rituximab therapy in patients with primary cytomegalovirus infection. 2015/12
90.	Original article	Retroperitoneal catecholamine-producing ganglioneuroma with a birth history of monozygotic twins who both suffered from neuroblastoma during their childhoods: A case report with genome analysis. 2015/10
91.	Original article	Anterior urethra sparing cystoprostatectomy for bladder cancer:a 10-year, single center experience. 2015/08
Display 5 items
Display all(91)

■ Academic conference presentation

1.	Comparison of the impacts of immune-related adverse events on the prognosis of patients with advanced renal cell carcinoma between patients treated with IO-IO and IO-TKI combination therapy.. 2023/04/29
2.	Outcome change in patients with advanced renal celcarcinoma outside of clinicalal trials from the tyrosine-kinase inhibitor era to the immune checkpoint inhibitor era. 2023/04/29
3.	Prognostic factors for recurrence after robot-assisted laparoscopic partial nephrectomy： Real-world data from Japanese single high-volume center. 2023/04/29
4.	Validation of predictive model for new baseline renal function after radical nephrectomy or robot-assisted partial nephrectomy in Japanese patients. 2023/04/29
5.	Prognostic factors for recurrence after robot-assisted laparoscopic partial nephrectomy: Real-world data from Japanese single high-volume center. 2023/04/21
6.	Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 RCC). A clinicopathological study of 10 Japanese cases. 2023/04/21
7.	Outcome in patients with advanced renal cell carcinoma treated with immunotherapy vs. tyrosine kinase inhibitor based on the status of chronic kidney disease. 2023/04/20
8.	Surgical outcomes for older patients with renal cell carcinoma and inferior vena cava thrombus. 2022/05/16
9.	Association between immune adverse events and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. 2022/05/13
10.	Association between ureteral clamping time and acute kidney injury during robot-assisted radical cystectomy. 2022/05/13
11.	C-reactive protein kinetics to predict recurrence after radical surgery for high-risk renal cell carcinoma. 2022/05/13
12.	Effects of first-line immune checkpoint inhibitors in patients with metastatic renal cell carcinoma not meeting trial eligibility criteria. 2022/05/13
13.	Potential survival benefit of deferred nephrectomy in patients treated with nivolumab plus ipilimumab for metastatic renal cell carcinoma. 2022/05/13
14.	Predictive impact of early changes in serum c-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. 2022/05/13
15.	Genetic and epigenetic alterations in renal cancers developing from end-stage renal disease. 2020/12/24
16.	Association between controlling nutritional status（CONUT）score and outcomes after radical cystectomy for advanced bladder cancer. 2020/12/23
17.	Association between early tumor response and survival in metastatic renal cell carcinoma treated with nivolumab. 2020/12/23
18.	Comparison of efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. 2020/12/23
19.	Safety and efficacy of nivolumab for patients with chronic kidney disease. 2020/12/23
20.	The predictive impact of presurgical sarcopenia on patient survival in patients with renal cell carcinoma with inferior vena cava tumor thrombus. 2020/12/23
21.	Genetic and epigenetic profiling reveals the proximal tubule origin of renal cancers in end-stage renal disease. 2020/10/01
22.	Comparisons of surgical outcomes between transperitoneal and retroperitoneal　approaches in robot-assisted laparoscopic partial nephrectomy for lateral renal tumors: A propensity score-matched comparative analysis. 2020/07/17
23.	Detection of a peritumoral pseudocapsule in patients with renal cell carcinoma undergoingrobot-assisted partial nephrectomy, using enhanced CT. 2020/07/17
24.	Predictive factors for recurrence after complete metastasectomy in patients with metastaticrenal cell carcinoma in the targeted therapy era. 2020/07/17
25.	Usefulness of robot-assisted laparoscopic partial nephrectomy using trifecta criteria. 2020/07/17
26.	The significance of microvascular inflammation in antibody-mediated rejection in ABO-incompatible kidney transplantation. 2016/06/13
27.	Sarcopenia and the modified glasgow prognostic score are significant predictors of patient survival in metastatic renal cell carcinoma patients receiving first-line sunitinib treatment. 2016/05/07
Display 5 items
Display all(27)

■ Awards & honors

2016

The American Transplant Congress 2016 American Transplant Congress Best Poster Award (Evaluation of Microvascular Inflammation in ABO-incompatible Kidney Transplantation)

■ Education

1.	2017/04～2021/03	〔Doctoral course〕, Tokyo Women's Medical University, Completed,
2.	2005/04～2011/03	Faculty of Medicine, Kanazawa University, Graduated

■ Rsearch funding number

20910821